CNS Drugs

Papers
(The H4-Index of CNS Drugs is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients158
Comment on: “A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy”129
Can Leucovorin (Folinic Acid) Treat Autism Features?122
Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing–Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weigh97
Apixaban for the Treatment of Cerebral Venous Sinus Thrombosis: A Single-Centre Experience and Systematic Review of the Literature84
Unmet Needs in Psychodermatology: A Narrative Review73
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuatio68
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?60
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies59
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines59
The Effect of Psychotropic Medications on Glaucoma Risk and Intraocular Pressure: A Bayesian Meta-Analysis56
Authors’ Reply to Abudayeh and Fishchenko: Comment on “Early High-Risk Opioid Prescribing and Persistent Opioid Use in Australian Workers with Workers’ Compensation Claims for Back and Neck Musculoske54
Managing Chronic Pain: The Ketamine Option53
Acknowledgement to Referees50
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis47
Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations46
Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine44
Subclinical Augmentation in Relation to Previous Dopaminergic Treatment in Patients with Restless Legs Syndrome: A Post Hoc Analysis of Two Randomized, Placebo-Controlled, Crossover Trials42
Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data42
Emerging Therapies for Angelman Syndrome42
Psychedelics for Patients Experiencing Existential Distress, Anxiety or Depression in Palliative Care39
Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders38
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder38
The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research36
Comment on: “Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder”36
Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Residual Sleepiness in Obstructive Sleep Apnea Despite Continuous Positive Airway Pressure: A Systematic Review a36
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis36
The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations35
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia34
Adjunctive Fenfluramine in Adults with Lennox–Gastaut Syndrome: Effectiveness and Tolerability in Real-World Clinical Practice33
A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder32
Therapeutic Use of γ-Hydroxybutyrate: History and Clinical Utility of Oxybates and Considerations of Once- and Twice-Nightly Dosing in Narcolepsy32
Narcolepsy: Beyond the Classic Pentad32
Comment on “A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder”'32
0.89733695983887